Adaptive and disease-focused trials and their practical application for clinical studies in chronic hepatitis B (CHB)

Seven drugs have been approved for treatment of chronic hepatitis B virus (HBV), but most patients still require lifelong therapy with virally targeted drugs. Although current treatments can suppress the virus, slow the progression to cirrhosis, reduce the incidence of liver cancer and improve long-term survival, they cannot eliminate the hepatitis B surface antigen (HBsAg); patients therefore require ongoing treatment.